The Institute of Cell Therapy at the Annual Meeting ISCT 2022, San Fransisco, USA
Prof. Alexandros Spyridonidis, Director and Dionysia Kefala, PhD candidate of the ICT, participated in the Annual Meeting ISCT 2022 San Fransisco, California, USA in May 2022.
Dionysia Kefala presented the study on “Pre-clinical development of a decitabine-induced regulatory HLAG+CD4+ T cell-enriched cell product (iG-Treg) against Graft-vs-Host-Disease” which was accepted as a brief oral presentation . She discussed the preclinical development and characterization of a novel cell product (iG-Tregs) against graft-versus-host disease, a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation. This cell product is soon to be evaluated in a phase I/II clinical study (EUDRACT 2021-006367-26).
Finally, studies by distinguished researchers in the field of cell and gene therapies were presented at the conference, giving rise to new research ideas.
